

April 25, 2025

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2025.

We request you to please take the same on record.

Thanking You,  
Yours Faithfully,

**For Dr. Lal PathLabs Limited**

**Vinay Gujral**  
**Company Secretary & Compliance Officer**

*Encl.: As above*

**Dr Lal PathLabs Limited records revenue of Rs 603 Cr in Q4 FY 2024-25**

New Delhi, India, April 25, 2025 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2025.

**Consolidated Performance Highlights: Q4 FY25 vs Q4 FY24**

- Revenue increased by 10.5% in Q4 FY25
- EBITDA increased by 16.9% with a margin of 28.1%
- PAT increased by 81.4% with a margin for of 25.8%
- Fourth Interim Dividend of Rs. 6 per share for FY25

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q4			Full Year		
	FY25	FY24	Gr %	FY25	FY24	Gr %
<b>Revenue</b>	<b>603</b>	<b>545</b>	<b>10.5%</b>	<b>2461</b>	<b>2227</b>	<b>10.5%</b>
Material consumed	118	109		481	451	
Employee benefit Expenses	115	106		482	425	
Fees to collection centres	78	76		342	313	
Other Expenses	123	111		460	428	
<b>EBITDA</b>	<b>169</b>	<b>145</b>	<b>16.9%</b>	<b>696</b>	<b>609</b>	<b>14.2%</b>
<i>Margins</i>	<i>28.1%</i>	<i>26.5%</i>		<i>28.3%</i>	<i>27.4%</i>	
Other Income	26	18		93	69	
Depreciation Cost	36	37		142	144	
Finance Cost	5	7		22	29	
<b>PBT</b>	<b>154</b>	<b>120</b>	<b>28.1%</b>	<b>625</b>	<b>505</b>	<b>23.6%</b>
<i>Margins</i>	<i>25.5%</i>	<i>22.0%</i>		<i>25.4%</i>	<i>22.7%</i>	
<i>Tax Current &amp; Deferred</i>	<i>39</i>	<i>34</i>		<i>174</i>	<i>143</i>	
<i>One-time Deferred Tax impact on SDIPL Voluntary Liquidation*</i>	<i>(41)</i>	<i>0</i>		<i>(41)</i>	<i>0</i>	
<b>PAT</b>	<b>156</b>	<b>86</b>	<b>81.4%</b>	<b>492</b>	<b>362</b>	<b>35.9%</b>
<i>Margins</i>	<i>25.8%</i>	<i>15.7%</i>		<i>20.0%</i>	<i>16.3%</i>	
<b>EPS</b>	<b>18.6</b>	<b>10.1</b>	<b>83.2%</b>	<b>58.5</b>	<b>43.0</b>	<b>35.9%</b>
<b>EPS (Normalised)*</b>	<b>13.6</b>	<b>10.1</b>	<b>34.1%</b>	<b>53.5</b>	<b>43.0</b>	<b>24.3%</b>

**About Dr Lal PathLabs Limited**

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

**Dr Lal Pathlabs Limited**

12<sup>th</sup> Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com



As on March 31, 2025 the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Goel  
Group Chief Financial Officer  
*Dr Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Kritika Khatwani  
*Adfactors PR*

+91 8604801332  
[kritika.khatwani@adfactorspr.com](mailto:kritika.khatwani@adfactorspr.com)

For further information on Dr Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

---

## Safe Harbour

---

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.